Literature DB >> 18709360

Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization.

Anne Dekeyne1, Mark J Millan.   

Abstract

RATIONALE: Though interoceptive properties of antidepressants have been described, discriminative stimulus (DS) properties of mirtazapine, which does not affect monoamine reuptake, remain uncharacterized.
OBJECTIVES: The objectives of the study are to train rats to recognize a mirtazapine DS, then perform substitution studies with other antidepressants and drugs acting at sites occupied by mirtazapine.
MATERIALS AND METHODS: Using a two-lever, fixed-ratio 10 schedule, rats were trained to discriminate mirtazapine (2.5 mg/kg, i.p.) from saline.
RESULTS: Sessions, 63 +/- 8, were necessary to reach the criterion for 14 rats that all subsequently recognized (100%) mirtazapine at the training dose. Mirtazapine blocks serotonin (5-HT)(2C) receptors, and the 5-HT(2C) antagonists, SB242,084, SB243,213 and S32006, revealed dose-dependent and full (> or =80%) substitution at doses of 2.5, 2.5, and 0.63 mg/kg, respectively. By contrast, the 5-HT(2A) antagonists, MDL100,907 and SR46349-B, the 5-HT(2B) antagonist, SB204,741, and the 5-HT(3) antagonist, ondansetron, showed no significant substitution. Though mirtazapine indirectly recruits 5-HT(1A) receptors, the 5-HT(1A) agonists, buspirone and 8-OH-DPAT, did not substitute. Mirtazapine blocks alpha(2)-adrenoceptors, but several alpha(2)-adrenoceptor antagonists (yohimbine, RX821,002 and atipamezole) failed to substitute. Despite blockade by mirtazapine of histamine H(1) receptors, no substitution was seen with the selective H(1) antagonist, pyrilamine. Finally, the selective noradrenaline reuptake inhibitor, reboxetine (0.16), fully substituted for mirtazapine, whereas the 5-HT/noradrenaline reuptake inhibitors, duloxetine and S33005, several 5-HT reuptake inhibitors (citalopram, fluvoxamine, and paroxetine) and the dopamine reuptake inhibitors, bupropion and GBR12,935, did not substitute.
CONCLUSION: Mirtazapine elicits a DS in rats for which selective antagonists at 5-HT(2C) receptors display dose-dependent substitution, whereas drugs acting at other sites recognized by mirtazapine are ineffective.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18709360     DOI: 10.1007/s00213-008-1259-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  81 in total

1.  Discriminative stimulus properties of eltoprazine.

Authors:  J Gommans; T H Hijzen; R A Maes; B Olivier
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

2.  Discriminative stimulus properties of the selective and highly potent alpha2-adrenoceptor agonist, S18616, in rats: mediation by the alpha2A subtype, and blockade by the atypical antidepressants, mirtazapine and mianserin.

Authors:  Anne Dekeyne; Mark J Millan
Journal:  Neuropharmacology       Date:  2006-06-30       Impact factor: 5.250

3.  Discriminative stimulus properties of tianeptine.

Authors:  Tevfik Alici; Hakan Kayir; M Oguz Aygoren; Esra Saglam; I Tayfun Uzbay
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

4.  Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.

Authors:  M J Millan; A Newman-Tancredi; V Audinot; D Cussac; F Lejeune; J P Nicolas; F Cogé; J P Galizzi; J A Boutin; J M Rivet; A Dekeyne; A Gobert
Journal:  Synapse       Date:  2000-02       Impact factor: 2.562

5.  Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors.

Authors:  Z Rogoz; A Wrobel; D Dlaboga; J Maj; M Dziedzicka-Wasylewska
Journal:  J Physiol Pharmacol       Date:  2002-03       Impact factor: 3.011

6.  Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.

Authors:  A Dekeyne; A Gobert; L Iob; L Cistarelli; C Melon; M J Millan
Journal:  Psychopharmacology (Berl)       Date:  2001-11       Impact factor: 4.530

Review 7.  Discriminative stimulus properties of antidepressant agents: a review.

Authors:  A Dekeyne; M J Millan
Journal:  Behav Pharmacol       Date:  2003-09       Impact factor: 2.293

8.  Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro.

Authors:  Stéphane Doly; Emmanuel Valjent; Vincent Setola; Jacques Callebert; Denis Hervé; Jean-Marie Launay; Luc Maroteaux
Journal:  J Neurosci       Date:  2008-03-12       Impact factor: 6.167

9.  Antagonism of the stimulus effects of yohimbine and 8-hydroxydipropylaminotetralin.

Authors:  J C Winter; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  1993-04       Impact factor: 3.533

Review 10.  Preclinical evidence on the psychotropic profile of fluvoxamine.

Authors:  B Olivier; L Bosch; A van Hest; J van der Heyden; J Mos; G van der Poel; J Schipper; M Tulp
Journal:  Pharmacopsychiatry       Date:  1993-05       Impact factor: 5.788

View more
  5 in total

1.  Mirtazapine alters cue-associated methamphetamine seeking in rats.

Authors:  Steven M Graves; T Celeste Napier
Journal:  Biol Psychiatry       Date:  2010-11-20       Impact factor: 13.382

2.  Drug discrimination: 30 years of progress.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2009-02-19       Impact factor: 4.530

Review 3.  Targeting of G-protein coupled receptors in sepsis.

Authors:  Abdul Rehman; Noor Ul-Ain Baloch; John P Morrow; Pál Pacher; György Haskó
Journal:  Pharmacol Ther       Date:  2020-03-19       Impact factor: 12.310

4.  Serotonin2C Receptors and the Motor Control of Oral Activity.

Authors:  Mélanie Lagière; Sylvia Navailles; Marion Bosc; Martin Guthrie; Philippe De Deurwaerdère
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

Review 5.  A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia.

Authors:  Kim Lawson
Journal:  Biomedicines       Date:  2017-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.